ShopSpell

Non-Myeloablative Allogeneic Transplantation [Paperback]

$90.99     $109.99    17% Off      (Free Shipping)
100 available
  • Category: Books (Medical)
  • ISBN-10:  1461353041
  • ISBN-10:  1461353041
  • ISBN-13:  9781461353041
  • ISBN-13:  9781461353041
  • Publisher:  Springer
  • Publisher:  Springer
  • Pages:  216
  • Pages:  216
  • Binding:  Paperback
  • Binding:  Paperback
  • Pub Date:  01-Feb-2012
  • Pub Date:  01-Feb-2012
  • SKU:  1461353041-11-SPRI
  • SKU:  1461353041-11-SPRI
  • Item ID: 100844132
  • List Price: $109.99
  • Seller: ShopSpell
  • Ships in: 5 business days
  • Transit time: Up to 5 business days
  • Delivery by: Jul 11 to Jul 13
  • Notes: Brand New Book. Order Now.
Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy relÓ#
Add Review